Tratamiento de molluscum contagiosum en enfermos inmunodeprimidos con cidofovirDos casos clinicos
- María del Rosario Mora Santiago
- M. García Coronel
- José Manuel Fernández Oviés
- Federico Tutau Gómez
- Begoña Muros
ISSN: 1139-7357
Año de publicación: 2000
Volumen: 2
Número: 2
Páginas: 170-173
Tipo: Artículo
Otras publicaciones en: Atención Farmacéutica
Resumen
Between June 1998 and March 1999 the Pharmacy Service applied for an anthorisation to use cidofovir in the treatment of Molluscum contagiosum within the 'compassionate use' protocol. An administration protocol was drawn up and the intravenous solution of the drug was prepared in the Pharmacy Service and in a vertical laminar flow bell: 5 mg/kg of body weight, via one hour intravenous infusion, once a week during two consecutive weeks (concomitant with oral probenecid and intravenous saline hydration). Maintenance dose: 5 mg/kg every two weeks. Intravenous cidofovir was administered to two immunosuppresed patients (one HIV+ patient and a patient with Variable Common Immune deficiency Syndrome), with Molluscum contagiosum that wasn't responding to traditional treatments. The doses given were 270 mg and 350 mg (total: 20 and 14 cycles, respectively). There was a satisfactory clinical response, which suggests that the drug is effective against the Molluscum contagiosum Virus